Silver MPN Center

Join Dr. Ellen Ritchie at the The Leukemia & Lymphoma Society National Virtual Conference where she’ll be speaking to patients, caregivers, and loved ones about ( ). Register and learn more here:

Welcome ,The Leukemia & Lymphoma Society is proud to present this free VIRTUAL education event to blood cancer patients, survivors, family members, caregivers, and healthcare professionals.* Experts in the areas of blood cancer research, treatment, and survivorship will present information on each topic....

The free The Leukemia & Lymphoma Society Tri-State Blood Cancer Conference for patients, loved ones and healthcare professionals is taking place on March 9 in NYC. Register to join Dr. Joseph Scandura and hear him speak about ( ): https://bit.ly/3T4vA0i

Dr. Joseph Scandura spoke with Targeted Oncology about the potential role of pelabresib for patients with and current evaluating this therapy option:

Pelabresib Generates Excitement in Myelofibrosis In an interview with Targeted Oncology, Joseph M. Scandura, MD, PhD, discussed research on pelabresib for the treatment of patients with myeloproliferative neoplasms.

Congratulations to Dr. Andrew Schafer for being selected as one of the 2023 CURE Today MPN Heroes for his dedication to research and care for patients with :

CURE Celebrates 8 Honorees at MPN Heroes Event CURE® honored eight MPN Heroes, which ranged from medical professionals to patients and caregivers, on the contributions they made in the field.

Dr. Ghaith Abu-Zeinah joined PV Reporter to break down what “disease modification” means for patients:

MPN Specialist Interview 2023 - MPN Cancer Connection MPN Specialist Dr. Abu-Zeinah unveils 'disease modification' and exciting late-stage clinical trials in this insightful interview.

How is Chronic Eosinophilic classified? Hear from Dr. Andrew Schaefer on how this type of manifests itself in the body:

What is Chronic Eosinophilic Leukemia? Chronic eosinophil diseases are types of blood disorders associated with abnormally high numbers of a rare white blood cell type called eosinophils. All heal...

Do you have questions about , including causes, symptoms, treatment, and more? The Weill Cornell Medicine Silver Center has answers: https://bit.ly/3OONsJM

is a type of chronic caused by abnormal blood stem cells that overproduce platelets:

Essential Thrombocythemia | Richard T. Silver MD Myeloproliferative Neoplasms Center Essential Thrombocythemia (ET) is a type of chronic myeloproliferative neoplasm caused by abnormal blood forming cells that overproduce a blood cell called platelets (aka thrombocytes). Like CML, ET is also thought to be caused by mutations in blood forming stem cells (aka hematopoietic stem cell, H...

breakthroughs have led to a number of treatment possibilities for that weren’t previously available: https://bit.ly/3Rt9ovvOther

People with can experience abnormal bleeding due to low platelet counts. Here’s what to know: https://bit.ly/3Y4hn4v

are characterized by abnormal cell growth, one of the classifications of . Learn more why are defined this way:

Are myeloproliferative neoplasms (MPNs) cancer? Cancer is caused by cells with abnormalities that grow and take over a part of tissue. Myeloproliferative neoplasms are considered cancer because they are ch...

Ruxolitinib is an oral medication used to treat and and works by blocking the excess JAK protein signaling that overproduces blood cells: https://bit.ly/3JFA2PW

Are hereditary? Learn more about the usual causes of :

Are MPNs hereditary? Most myeloproliferative neoplasm cases are not hereditary and are almost always caused by gene mutations acquired in a blood stem cell over time. JAK2 is the...

Side effects of vary from person to person. These are some of the common ones:

What are some of the common side effects of MPNs? Every individual diagnosed with a myeloproliferative neoplasm may experience different side effects. Side effects can range from more serious, such as fever,...

Did you know that chronic neutrophilic (CNL) is a very rare caused by an overproduction of a type of white blood cell called neutrophils? Learn more:

Chronic Neutrophilic Leukemia | Richard T. Silver MD Myeloproliferative Neoplasms Center Chronic neutrophilic leukemia (CNL) is a very rare myeloproliferative neoplasm (MPN) classified by an overproduction of neutrophils in the bone marrow. Neutrophils are the most common types of white blood cells in the body and protect the immune system. If the body is fighting an infection, it will....

have the ability to transform from one type to another due to mutations in the cells. Learn more about this process via Dr. Ellen Ritchie:

How do MPNs change from one MPN to another? Myeloproliferative neoplasms are chronic disorders causing excess production of blood cells. These disorders have the ability to transform from one type to a...

Tyrosine kinase inhibitors (TKIs) are a type of targeted therapy that can be used to treat certain types of : https://bit.ly/3vDHjHI

Dr. Joseph Scandura breaks down the goals of treatment and what to consider when choosing a therapy:

Finding an MPN Treatment Approach That Is Right for You - Patient Empowerment Network Dr. Joseph Scandura reviews the goals of MPN treatment and factors that should be considered when choosing a therapy.

Some patients may experience intermittent, constant, or unpredictable itching. Here’s what to know about the condition also known as pruritis: https://bit.ly/3GEvRlp

Have questions about ? Hear from Dr. Ghaith Abu-Zeinah as he breaks down the characteristics, symptoms, and treatments of this :

What is Polycythemia Vera (PV)? Polycythemia vera (PV) is a slow growing blood cancer characterized by an overproduction of red blood cells. The excess cells thicken the blood, slowing down...

WATCH: Dr. Joseph Scandura joined Patient Power to talk through the most important presentations from , including new therapies, combination treatments, and what to follow in the new year:

2022 ASH: Myelofibrosis Roundtable Following the conclusion of the American Society of Hematology (ASH) Annual Meeting, experts discuss most important presentations for myelofibrosis patients.

With appropriate management, most pregnant patients with can deliver healthy babies, but there are associated risks to monitor. The Weill Cornell Medicine Silver MPN Center team collaborates closely with specialty obstetricians to individualize care: https://bit.ly/3UfA0zX

A mutation of the JAK2 protein is found in nearly all people with and in many people with and . This mutation causes an excess of blood cells in the body, which can lead to other complications:

What is a JAK2 mutation? JAK2 is a protein linked to several receptors on blood cells. JAK2 mediates the signal that a blood cell receives in order to differentiate into a more matur...

Imatinib was the first drug approved by the FDA to target the BCR-ABL tyrosine kinase protein seen in chronic myeloid and is still used today as the standard of care for these patients. Learn more from Dr. Richard T. Silver:

What is Imatinib? Imatinib is an oral Tyrosine kinase inhibitor (TKI) medication that targets the BCR-ABL protein present in chronic myeloid leukemia (CML) patients. In 2000, ...

Newly diagnosed with ? Read the Weill Cornell Medicine Silver Center’s guide for patients and loved ones: https://bit.ly/3HTw01F

A number of ongoing research initiatives and are underway that aimed at to advance ing treatment options for . Dr. Joseph Scandura breaks down these developments via CURE Today:

Ongoing Research May Lead to ‘Exciting’ Advancements for Myelofibrosis Years Down the Line Research efforts will improve the lives of patients with myelofibrosis, though those advancements may take years to come, an expert said.

WATCH: Dr. Joseph Scandura gave an overview of research presented at on the BET inhibitor pelabresib, including his own work evaluating pelabresib for :

Updated Data of Pelabresib in Myelofibrosis Joseph M. Scandura, MD, PhD, provides an overview on the research of pelabresib which will be discussed at the 2022 American Society of Hematology Annual Meeting.

Congratulations to Weill Cornell Medicine Silver MPN Center team member Dr. Ghaith Abu-Zeinah for being selected as a 2022 MPN Hero by Voices of MPN for his dedication to personalized patient care and research: https://bit.ly/3WoFU3g

ICYMI: Weill Cornell Medicine Silver MPN Center team members were involved with a number of research studies presented at . Read more about our team’s involvement this year: https://bit.ly/3j8M3lL